Selected research
Market Structure
Global Human Papillomavirus Protein E7 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Human Papillomavirus Protein E7 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Human Papillomavirus Protein E7 include VLPbio, Transgene SA, Touchlight Genetics Ltd, Selecta Biosciences Inc, MedImmune LLC, Inovio Pharmaceuticals Inc, Immunovaccine Inc, iBio Inc and Hookipa Biotech AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Human Papillomavirus Protein E7 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Human Papillomavirus Protein E7 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human Papillomavirus Protein E7 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Papillomavirus Protein E7 market size, projected growth trends, production technologies, key applications, and end-use industries.
Human Papillomavirus Protein E7 Segment by Company
VLPbio
Transgene SA
Touchlight Genetics Ltd
Selecta Biosciences Inc
MedImmune LLC
Inovio Pharmaceuticals Inc
Immunovaccine Inc
iBio Inc
Hookipa Biotech AG
Genexine Inc
Formune SL
Etubics Corp
Cancer Research Technology Ltd
BioNTech AG
Bioleaders Corp
Advaxis Inc
Abion Inc
Human Papillomavirus Protein E7 Segment by Type
CUE-201
CerviVax
CUE-101
BLSILSB-710c
Others
Human Papillomavirus Protein E7 Segment by Application
Rectal Cancer
Penile Cancer
Anal Cancer
Lung Cancer
Others
Human Papillomavirus Protein E7 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Papillomavirus Protein E7 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Papillomavirus Protein E7 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Papillomavirus Protein E7.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Human Papillomavirus Protein E7 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Papillomavirus Protein E7 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Papillomavirus Protein E7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Human Papillomavirus Protein E7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- CUE-201
- CerviVax
- CUE-101
- BLSILSB-710c
- Others
Applications
- Rectal Cancer
- Penile Cancer
- Anal Cancer
- Lung Cancer
- Others
Companies covered
- VLPbio
- Transgene SA
- Touchlight Genetics Ltd
- Selecta Biosciences Inc
- MedImmune LLC
- Inovio Pharmaceuticals Inc
- Immunovaccine Inc
- iBio Inc
- Hookipa Biotech AG
- Genexine Inc
- Formune SL
- Etubics Corp
- Cancer Research Technology Ltd
- BioNTech AG
- Bioleaders Corp
- Advaxis Inc
- Abion Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Human Papillomavirus Protein E7 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Human Papillomavirus Protein E7 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Human Papillomavirus Protein E7 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Human Papillomavirus Protein E7 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Human Papillomavirus Protein E7 Market Dynamics
- 2.1 Human Papillomavirus Protein E7 Industry Trends
- 2.2 Human Papillomavirus Protein E7 Industry Drivers
- 2.3 Human Papillomavirus Protein E7 Industry Opportunities and Challenges
- 2.4 Human Papillomavirus Protein E7 Industry Restraints
3 Human Papillomavirus Protein E7 Market by Manufacturers
- 3.1 Global Human Papillomavirus Protein E7 Revenue by Manufacturers (2021-2026)
- 3.2 Global Human Papillomavirus Protein E7 Sales by Manufacturers (2021-2026)
- 3.3 Global Human Papillomavirus Protein E7 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Human Papillomavirus Protein E7 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Human Papillomavirus Protein E7 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Human Papillomavirus Protein E7 Manufacturers, Product Type & Application
- 3.7 Global Human Papillomavirus Protein E7 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Human Papillomavirus Protein E7 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Human Papillomavirus Protein E7 Players Market Share by Revenue in 2025
- 3.8.3 2025 Human Papillomavirus Protein E7 Tier 1, Tier 2, and Tier 3
4 Human Papillomavirus Protein E7 Market by Type
- 4.1 Human Papillomavirus Protein E7 Type Introduction
- 4.1.1 CUE-201
- 4.1.2 CerviVax
- 4.1.3 CUE-101
- 4.1.4 BLSILSB-710c
- 4.1.5 Others
- 4.2 Global Human Papillomavirus Protein E7 Sales by Type
- 4.2.1 Global Human Papillomavirus Protein E7 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Human Papillomavirus Protein E7 Sales by Type (2021-2032)
- 4.2.3 Global Human Papillomavirus Protein E7 Sales Market Share by Type (2021-2032)
- 4.3 Global Human Papillomavirus Protein E7 Revenue by Type
- 4.3.1 Global Human Papillomavirus Protein E7 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Human Papillomavirus Protein E7 Revenue by Type (2021-2032)
- 4.3.3 Global Human Papillomavirus Protein E7 Revenue Market Share by Type (2021-2032)
5 Human Papillomavirus Protein E7 Market by Application
- 5.1 Human Papillomavirus Protein E7 Application Introduction
- 5.1.1 Rectal Cancer
- 5.1.2 Penile Cancer
- 5.1.3 Anal Cancer
- 5.1.4 Lung Cancer
- 5.1.5 Others
- 5.2 Global Human Papillomavirus Protein E7 Sales by Application
- 5.2.1 Global Human Papillomavirus Protein E7 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Human Papillomavirus Protein E7 Sales by Application (2021-2032)
- 5.2.3 Global Human Papillomavirus Protein E7 Sales Market Share by Application (2021-2032)
- 5.3 Global Human Papillomavirus Protein E7 Revenue by Application
- 5.3.1 Global Human Papillomavirus Protein E7 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Human Papillomavirus Protein E7 Revenue by Application (2021-2032)
- 5.3.3 Global Human Papillomavirus Protein E7 Revenue Market Share by Application (2021-2032)
6 Global Human Papillomavirus Protein E7 Sales by Region
- 6.1 Global Human Papillomavirus Protein E7 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Human Papillomavirus Protein E7 Sales by Region (2021-2032)
- 6.2.1 Global Human Papillomavirus Protein E7 Sales by Region (2021-2026)
- 6.2.2 Global Human Papillomavirus Protein E7 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Human Papillomavirus Protein E7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Human Papillomavirus Protein E7 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Human Papillomavirus Protein E7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Human Papillomavirus Protein E7 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Human Papillomavirus Protein E7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Human Papillomavirus Protein E7 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Human Papillomavirus Protein E7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Human Papillomavirus Protein E7 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Human Papillomavirus Protein E7 Revenue by Region
- 7.1 Global Human Papillomavirus Protein E7 Revenue by Region
- 7.1.1 Global Human Papillomavirus Protein E7 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Human Papillomavirus Protein E7 Revenue by Region (2021-2026)
- 7.1.3 Global Human Papillomavirus Protein E7 Revenue by Region (2027-2032)
- 7.1.4 Global Human Papillomavirus Protein E7 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Human Papillomavirus Protein E7 Revenue (2021-2032)
- 7.2.2 North America Human Papillomavirus Protein E7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Human Papillomavirus Protein E7 Revenue (2021-2032)
- 7.3.2 Europe Human Papillomavirus Protein E7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Human Papillomavirus Protein E7 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Human Papillomavirus Protein E7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Human Papillomavirus Protein E7 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Human Papillomavirus Protein E7 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 VLPbio
- 8.1.1 VLPbio Company Information
- 8.1.2 VLPbio Business Overview
- 8.1.3 VLPbio Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 VLPbio Human Papillomavirus Protein E7 Product Portfolio
- 8.1.5 VLPbio Recent Developments
- 8.2 Transgene SA
- 8.2.1 Transgene SA Company Information
- 8.2.2 Transgene SA Business Overview
- 8.2.3 Transgene SA Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Transgene SA Human Papillomavirus Protein E7 Product Portfolio
- 8.2.5 Transgene SA Recent Developments
- 8.3 Touchlight Genetics Ltd
- 8.3.1 Touchlight Genetics Ltd Company Information
- 8.3.2 Touchlight Genetics Ltd Business Overview
- 8.3.3 Touchlight Genetics Ltd Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Touchlight Genetics Ltd Human Papillomavirus Protein E7 Product Portfolio
- 8.3.5 Touchlight Genetics Ltd Recent Developments
- 8.4 Selecta Biosciences Inc
- 8.4.1 Selecta Biosciences Inc Company Information
- 8.4.2 Selecta Biosciences Inc Business Overview
- 8.4.3 Selecta Biosciences Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Selecta Biosciences Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.4.5 Selecta Biosciences Inc Recent Developments
- 8.5 MedImmune LLC
- 8.5.1 MedImmune LLC Company Information
- 8.5.2 MedImmune LLC Business Overview
- 8.5.3 MedImmune LLC Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 MedImmune LLC Human Papillomavirus Protein E7 Product Portfolio
- 8.5.5 MedImmune LLC Recent Developments
- 8.6 Inovio Pharmaceuticals Inc
- 8.6.1 Inovio Pharmaceuticals Inc Company Information
- 8.6.2 Inovio Pharmaceuticals Inc Business Overview
- 8.6.3 Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.6.5 Inovio Pharmaceuticals Inc Recent Developments
- 8.7 Immunovaccine Inc
- 8.7.1 Immunovaccine Inc Company Information
- 8.7.2 Immunovaccine Inc Business Overview
- 8.7.3 Immunovaccine Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Immunovaccine Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.7.5 Immunovaccine Inc Recent Developments
- 8.8 iBio Inc
- 8.8.1 iBio Inc Company Information
- 8.8.2 iBio Inc Business Overview
- 8.8.3 iBio Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 iBio Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.8.5 iBio Inc Recent Developments
- 8.9 Hookipa Biotech AG
- 8.9.1 Hookipa Biotech AG Company Information
- 8.9.2 Hookipa Biotech AG Business Overview
- 8.9.3 Hookipa Biotech AG Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Hookipa Biotech AG Human Papillomavirus Protein E7 Product Portfolio
- 8.9.5 Hookipa Biotech AG Recent Developments
- 8.10 Genexine Inc
- 8.10.1 Genexine Inc Company Information
- 8.10.2 Genexine Inc Business Overview
- 8.10.3 Genexine Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Genexine Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.10.5 Genexine Inc Recent Developments
- 8.11 Formune SL
- 8.11.1 Formune SL Company Information
- 8.11.2 Formune SL Business Overview
- 8.11.3 Formune SL Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Formune SL Human Papillomavirus Protein E7 Product Portfolio
- 8.11.5 Formune SL Recent Developments
- 8.12 Etubics Corp
- 8.12.1 Etubics Corp Company Information
- 8.12.2 Etubics Corp Business Overview
- 8.12.3 Etubics Corp Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Etubics Corp Human Papillomavirus Protein E7 Product Portfolio
- 8.12.5 Etubics Corp Recent Developments
- 8.13 Cancer Research Technology Ltd
- 8.13.1 Cancer Research Technology Ltd Company Information
- 8.13.2 Cancer Research Technology Ltd Business Overview
- 8.13.3 Cancer Research Technology Ltd Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Cancer Research Technology Ltd Human Papillomavirus Protein E7 Product Portfolio
- 8.13.5 Cancer Research Technology Ltd Recent Developments
- 8.14 BioNTech AG
- 8.14.1 BioNTech AG Company Information
- 8.14.2 BioNTech AG Business Overview
- 8.14.3 BioNTech AG Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 BioNTech AG Human Papillomavirus Protein E7 Product Portfolio
- 8.14.5 BioNTech AG Recent Developments
- 8.15 Bioleaders Corp
- 8.15.1 Bioleaders Corp Company Information
- 8.15.2 Bioleaders Corp Business Overview
- 8.15.3 Bioleaders Corp Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Bioleaders Corp Human Papillomavirus Protein E7 Product Portfolio
- 8.15.5 Bioleaders Corp Recent Developments
- 8.16 Advaxis Inc
- 8.16.1 Advaxis Inc Company Information
- 8.16.2 Advaxis Inc Business Overview
- 8.16.3 Advaxis Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Advaxis Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.16.5 Advaxis Inc Recent Developments
- 8.17 Abion Inc
- 8.17.1 Abion Inc Company Information
- 8.17.2 Abion Inc Business Overview
- 8.17.3 Abion Inc Human Papillomavirus Protein E7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Abion Inc Human Papillomavirus Protein E7 Product Portfolio
- 8.17.5 Abion Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Human Papillomavirus Protein E7 Value Chain Analysis
- 9.1.1 Human Papillomavirus Protein E7 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Human Papillomavirus Protein E7 Production Mode & Process
- 9.2 Human Papillomavirus Protein E7 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Human Papillomavirus Protein E7 Distributors
- 9.2.3 Human Papillomavirus Protein E7 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst